I'm not following?
If a trial demonstrates a benefit for < 65 (which are the majority of patients), on the primary endpoint (mortality), then why do you think this be ignored?
I'm not following?If a trial demonstrates a benefit for < 65...
-
- There are more pages in this discussion • 1,571 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $11.91M | 10.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 98324 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 39688 | 5 |
View Market Depth
| Last trade - 15.22pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |